In this study, we demonstrated the novel finding that miRNA-186 may serve as a potential molecular marker associated with disease activity exacerbation and may be useful for diagnosing patients with rheumatoid arthritis in whom the ACPA has not been detected. Here, PRTN3 is linked to rheumatoid arthritis.